Objectives: The aim of this study was to determine the prevalence of hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (anti-HBc) and hepatitis B virus (HBV) DNA among a selected group of Omani blood donors.
Materials And Methods: Two hundred HBsAg-negative donors were screened for anti-HBc. Those found to be positive were investigated for HBV DNA by polymerase chain reaction. HBsAg was retested on these sera following an immune complex dissociation technique.
Results: HBsAg was present in 2.8% of the donors. Forty-one out of 200 (20.5%) HBsAg-negative donors were positive for anti-HBc. Eleven were positive for HBsAg after dissociation, whereas 8 gave readings just over the cutoff. HBV DNA was not detected in this group.
Conclusion: Findings indicate that testing donors for HBsAg alone is not sufficient to eliminate HBV from the blood supply in Oman.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000094271 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Cell-penetrating bispecific antibody suppresses hepatitis B virus replication and secretion.
Virus Res
January 2025
Medical Research Center, Yuebei People's Hospital, Shantou University Medical College, 512025, Shaoguan, China; Shenzhen Immuthy Biotech Co., Ltd, 518107, Shenzhen, Guangdong, China. Electronic address:
Hepatitis B virus (HBV) represents one of the major pathogenic factor that leads to chronic liver diseases and the development of hepatocellular carcinoma (HCC). The currently approved anti-HBV drugs cannot eradicate the virus or block the development of HCC. HBV nucleocapsid consists of the hepatitis B core antigen (HBcAg) and the HBV relaxed-circular partially double-stranded DNA (rcDNA), indispensable in virus replication.
View Article and Find Full Text PDFSerological and Molecular Characterization of the Hepatitis B Virus in Blood Donors in Maputo City, Mozambique.
Viruses
January 2025
Instituto Nacional de Saúde of Mozambique, EN1, Bairro da Vila, Marracuene 3943, Mozambique.
Hepatitis B virus (HBV) is a major public health concern responsible for hepatitis and hepatocellular carcinoma (HCC) worldwide. In Mozambique, HBsAg prevalence is high and endemic, and despite the strategies to mitigate the spread of the disease, the HCC incidence is still high and one of the highest in the world. There is still limited data on the serological profile and molecular epidemiology of HBV in Mozambique given the burden of this disease.
View Article and Find Full Text PDFHepatitis B Virus in Polish Blood Donors in the Period 2005-2019-Significant Changes in Epidemiology and Demographic Characteristics of Infected Donors.
Viruses
January 2025
Department of Virology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland.
In the 1980s, Poland was a medium-endemic country, with one of the highest incidences of hepatitis B in Europe (45/10 inhabitants). Pursuant to the WHO guidelines, obligatory vaccination was introduced in 1994-1996 (as a part of hepatitis B prophylaxis for newborns), and in 2000-2011, all 14-year-olds were vaccinated. To prevent transfusion-transmitted HBV infection (TT-HBV), since the 1970s, each donation has been tested for HBsAg and, since 2005, additionally for the presence of HBV DNA.
View Article and Find Full Text PDFMolecular Epidemiology, Drug-Resistant Variants, and Therapeutic Implications of Hepatitis B Virus and Hepatitis D Virus Prevalence in Nigeria: A National Study.
Pathogens
January 2025
Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.
Information on circulating HBV (sub-)genotype, variants, and hepatitis D virus (HDV) coinfection, which vary by geographical area, is crucial for the efficient control and management of HBV. We investigated the genomic characteristics of HBV (with a prevalence of 8.1%) and the prevalence of HDV in Nigeria.
View Article and Find Full Text PDFSurveillance Following Hepatitis B Surface Antigen Loss: An Issue Requiring Attention.
Pathogens
December 2024
Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan 430030, China.
Due to the lack of agents that directly target covalently closed circular DNA and integrated HBV DNA in hepatocytes, achieving a complete cure for chronic hepatitis B (CHB) remains challenging. The latest guidelines recommend (hepatitis B surface antigen) HBsAg loss as the ideal treatment target for improving liver function, histopathology, and long-term prognosis. However, even after HBsAg loss, hepatitis B virus can persist, with a risk of recurrence, reactivation, cirrhosis, and hepatocellular carcinoma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!